Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA.
Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA.
Int J Med Sci. 2020 Oct 18;17(18):2974-2986. doi: 10.7150/ijms.50537. eCollection 2020.
In the ongoing COVID-19 pandemic, all COVID-19 patients are naïve patients as it is the first-time humans have been exposed to the SARS-CoV-2 virus. As with exposure to many viruses, individuals with pre-existing, compromised immune systems may be at increased risk of developing severe symptoms and/or dying because of (SARS-CoV-2) infection. To learn more about such individuals, we conducted a search and review of published reports on the clinical characteristics and outcomes of COVID-19 patients with pre-existing, compromised immune systems. Here we present our review of patients who possess pre-existing primary antibody deficiency (PAD) and those who are organ transplant recipients on maintenance immunosuppressants. Our review indicates different clinical outcomes for the patients with pre-existing PAD, depending on the underlying causes. For organ transplant recipients, drug-induced immune suppression alone does not appear to enhance COVID-19 mortality risk - rather, advanced age, comorbidities, and the development of secondary complications appears required.
在持续的 COVID-19 大流行中,所有 COVID-19 患者都是初次感染 SARS-CoV-2 病毒的患者。与接触许多病毒一样,由于(SARS-CoV-2)感染,免疫系统存在先天缺陷或受损的个体可能面临更严重症状和/或死亡的风险。为了更多地了解此类人群,我们对已发表的有关先天免疫系统受损的 COVID-19 患者的临床特征和结局的报告进行了检索和综述。在这里,我们综述了患有原发性抗体缺陷(PAD)和正在接受维持免疫抑制治疗的器官移植受者的患者。我们的综述表明,患有 PAD 的患者的临床结局因潜在病因而异。对于器官移植受者,药物引起的免疫抑制本身似乎不会增加 COVID-19 的死亡风险,而是需要高龄、合并症和继发并发症的出现。